Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Free Cash Flow: 2011-2025

Historic Free Cash Flow for Niagen Bioscience (NAGE) over the last 12 years, with Sep 2025 value amounting to $3.7 million.

  • Niagen Bioscience's Free Cash Flow rose 6.20% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.1 million, marking a year-over-year increase of 420.89%. This contributed to the annual value of $11.9 million for FY2024, which is 71.42% up from last year.
  • According to the latest figures from Q3 2025, Niagen Bioscience's Free Cash Flow is $3.7 million, which was up 234.06% from $1.1 million recorded in Q2 2025.
  • Niagen Bioscience's 5-year Free Cash Flow high stood at $8.5 million for Q4 2024, and its period low was -$8.2 million during Q2 2021.
  • In the last 3 years, Niagen Bioscience's Free Cash Flow had a median value of $2.7 million in 2023 and averaged $2.9 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first slumped by 1,886.35% in 2021, then spiked by 2,997.64% in 2025.
  • Over the past 5 years, Niagen Bioscience's Free Cash Flow (Quarterly) stood at -$4.9 million in 2021, then surged by 89.89% to -$500,000 in 2022, then soared by 225.60% to $628,000 in 2023, then spiked by 1,255.73% to $8.5 million in 2024, then grew by 6.20% to $3.7 million in 2025.
  • Its last three reported values are $3.7 million in Q3 2025, $1.1 million for Q2 2025, and $7.9 million during Q1 2025.